Drug intelligence / Profile preview

CYTO NK-201

Development stage: Preclinical
Lead developer: CytoImmune Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CYTO NK-201 is an allogeneic, off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by CytoImmune Therapeutics. It is engineered to target FMS-like tyrosine kinase 3 (FLT3), a receptor commonly expressed in certain hematologic malignancies. The therapy aims to provide immunologic cytotoxicity and act as a natural killer cell replacement by directly killing cancer cells and stimulating broader immune responses. Its primary indication under development is acute myeloid leukemia (AML). As of the latest updates, the drug remains in preclinical development[1][2][3].

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on CYTO NK-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYTO NK-201.

Explore the full profile